Total Payments
$4,774
2024 Payments
$757.07
Companies
13
Transactions
223
Medicare Patients
1,100
Medicare Billing
$110,011
Payment Breakdown by Category
Food & Beverage$4,747 (99.4%)
Education$27.27 (0.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,747 | 222 | 99.4% |
| Education | $27.27 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $1,227 | 38 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $775.39 | 22 | $0 (2024) |
| ABBVIE INC. | $769.10 | 56 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $504.54 | 34 | $0 (2022) |
| Vanda Pharmaceuticals Inc. | $344.46 | 22 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $344.34 | 16 | $0 (2024) |
| Alkermes, Inc. | $293.01 | 12 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $280.66 | 11 | $0 (2024) |
| ITI, Inc. | $98.63 | 6 | $0 (2023) |
| Lundbeck LLC | $42.68 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $757.07 | 33 | ABBVIE INC. ($302.58) |
| 2023 | $1,239 | 39 | Otsuka America Pharmaceutical, Inc. ($437.14) |
| 2022 | $991.99 | 57 | Janssen Pharmaceuticals, Inc ($201.79) |
| 2021 | $1,786 | 94 | Otsuka America Pharmaceutical, Inc. ($412.21) |
All Payment Transactions
223 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Education | In-kind items and services | $27.27 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: Neurology | ||||||
| 11/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $7.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.20 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $7.22 | General |
| Category: PSYCHIATRY | ||||||
| 10/21/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: PSYCHIATRY | ||||||
| 10/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.96 | General |
| Category: NEUROSCIENCE | ||||||
| 09/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.64 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: NEUROSCIENCE | ||||||
| 08/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: NEUROSCIENCE | ||||||
| 06/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: NEUROSCIENCE | ||||||
| 06/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.44 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.08 | General |
| Category: NEUROSCIENCE | ||||||
| 05/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: NEUROSCIENCE | ||||||
| 05/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: PSYCHIATRY | ||||||
| 04/23/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $29.23 | General |
| Category: Neuroscience | ||||||
| 04/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: PSYCHIATRY | ||||||
| 04/17/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $101.19 | General |
| Category: PSYCHIATRY | ||||||
| 04/15/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: Neurology | ||||||
| 04/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: NEUROSCIENCE | ||||||
| 04/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.74 | General |
| Category: NEUROSCIENCE | ||||||
| 04/01/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 149 | 249 | $17,770 | $9,974 |
| 2022 | 8 | 316 | 799 | $48,138 | $28,582 |
| 2021 | 7 | 288 | 759 | $47,378 | $31,141 |
| 2020 | 8 | 347 | 1,254 | $84,959 | $40,314 |
Total Patients
1,100
Total Services
3,061
Medicare Billing
$110,011
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 105 | $8,652 | $5,281 | 61.0% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 22 | 22 | $3,316 | $1,934 | 58.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 57 | $3,046 | $1,235 | 40.6% |
| 90832 | Psychotherapy, 30 minutes | Office | 2023 | 25 | 25 | $1,687 | $911.93 | 54.0% |
| 90853 | Group psychotherapy | Office | 2023 | 21 | 40 | $1,069 | $611.68 | 57.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 75 | 193 | $10,294 | $6,027 | 58.6% |
| 90853 | Group psychotherapy | Office | 2022 | 37 | 338 | $9,031 | $5,178 | 57.3% |
| 90837 | Psychotherapy, 1 hour | Office | 2022 | 31 | 58 | $7,819 | $5,159 | 66.0% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 56 | 58 | $8,742 | $5,029 | 57.5% |
| 90832 | Psychotherapy, 30 minutes | Office | 2022 | 63 | 86 | $5,833 | $3,565 | 61.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 32 | $2,637 | $1,425 | 54.0% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2022 | 16 | 16 | $2,162 | $1,281 | 59.3% |
| 90834 | Psychotherapy, 45 minutes | Office | 2022 | 18 | 18 | $1,620 | $917.15 | 56.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 78 | 210 | $11,222 | $7,038 | 62.7% |
| 90837 | Psychotherapy, 60 minutes | Office | 2021 | 31 | 67 | $9,034 | $5,887 | 65.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 49 | 49 | $7,385 | $5,298 | 71.7% |
| 90853 | Group psychotherapy | Office | 2021 | 21 | 273 | $7,295 | $4,455 | 61.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 67 | $5,521 | $3,692 | 66.9% |
| 90832 | Psychotherapy, 30 minutes | Office | 2021 | 55 | 72 | $5,031 | $3,375 | 67.1% |
| 90834 | Psychotherapy, 45 minutes | Office | 2021 | 18 | 21 | $1,890 | $1,396 | 73.9% |
| 90853 | Group psychotherapy | Office | 2020 | 40 | 672 | $27,487 | $11,341 | 41.3% |
| 90837 | Psychotherapy, 60 minutes | Office | 2020 | 31 | 78 | $13,255 | $6,691 | 50.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 98 | 230 | $14,367 | $6,438 | 44.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 50 | 83 | $7,057 | $5,192 | 73.6% |
| 90832 | Psychotherapy, 30 minutes | Office | 2020 | 54 | 101 | $8,509 | $4,152 | 48.8% |
About Ashley Sneed
Ashley Sneed is a Psychiatric/Mental Health healthcare provider based in Texarkana, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/27/2015. The National Provider Identifier (NPI) number assigned to this provider is 1669849493.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ashley Sneed has received a total of $4,774 in payments from pharmaceutical and medical device companies, with $757.07 received in 2024. These payments were reported across 223 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($4,747).
As a Medicare-enrolled provider, Sneed has provided services to 1,100 Medicare beneficiaries, totaling 3,061 services with total Medicare billing of $110,011. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatric/Mental Health
- Location Texarkana, AR
- Active Since 08/27/2015
- Last Updated 09/04/2025
- Taxonomy Code 363LP0808X
- Entity Type Individual
- NPI Number 1669849493
Products in Payments
- VRAYLAR (Drug) $752.29
- ABILIFY MAINTENA (Drug) $551.52
- REXULTI (Drug) $508.69
- LATUDA (Drug) $504.54
- SPRAVATO (Drug) $491.28
- INGREZZA (Drug) $344.34
- HETLIOZ (Drug) $314.49
- INVEGA SUSTENNA (Drug) $255.60
- AUSTEDO (Drug) $242.42
- ABILIFY ASIMTUFII (Drug) $209.51
- ARISTADA (Drug) $163.51
- CAPLYTA (Drug) $138.13
- LYBALVI (Drug) $129.50
- UZEDY (Drug) $38.24
- FANAPT (Drug) $29.97
- INVEGA TRINZA (Drug) $28.51
- PERSERIS (Drug) $27.43
- COBENFY (Drug) $27.27
- UBRELVY (Drug) $16.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatric/Mental Health Doctors in Texarkana
Elizabeth Hardy, Aprn, APRN
Psychiatric/Mental Health — Payments: $6,151
Psychiatric/Mental Health $6,151
Jody Barham, Apn, APN
Psychiatric/Mental Health — Payments: $1,249
Psychiatric/Mental Health $1,249
Carol Tatum, Anp Cns, ANP CNS
Psychiatric/Mental Health — Payments: $1,037
Psychiatric/Mental Health $1,037
Grant Barnett, Mnsc, Aprn, Pmhnp-Bc, MNSC, APRN, PMHNP-BC
Psychiatric/Mental Health — Payments: $555.33
Psychiatric/Mental Health $555.33
Ms. Gracie Adkisson, Pmhnp-Bc, PMHNP-BC
Psychiatric/Mental Health — Payments: $231.17
Psychiatric/Mental Health $231.17
Jennifer Robinson, Aprn, Pmhnp-Bc, APRN, PMHNP-BC
Psychiatric/Mental Health — Payments: $210.99
Psychiatric/Mental Health $210.99